June 25 (Reuters) - Merck KGaA has agreed to
acquire biotech firm Bio-Techne Corp ( TECH ) for $11.3 billion,
the German science and healthcare firm said in a statement on
Thursday.
Shares of Bio-Techne ( TECH ) rose 22% in premarket trading.
The offer price of $73 per share implies a 24% premium to
Bio-Techne's ( TECH ) close on Wednesday.
The acquisition would expand Merck's presence in
life-science research. Bio-Techne ( TECH ) supplies research reagents,
proteins, antibodies, analytical instruments and other tools
used by scientists and drug developers.
The German firm said it would fund the acquisition through a
combination of existing cash and new debt.
(Reporting by Danny Callaghan, Christy Santhosh and Padmanabhan
Ananthan; Editing by Linda Pasquini and Shinjini Ganguli)